Ganglioside biosynthetic pathway

Ganglioside biosynthesis is the metabolic process by which ceramide is converted into complex sialic acid-containing glycosphingolipids, primarily occurring within the Golgi apparatus. The pathway is initiated by the enzyme glucosylceramide synthase (UGCG), which catalyzes the glucosylation of ceramide, followed by the action of various glycosyltransferases and sialyltransferases that define the specific ganglioside series (e.g., a, b, and c-series) [1][2]. These molecules are essential components of the plasma membrane, particularly in the central nervous system, where they modulate cell signaling, neuronal adhesion, and synaptic plasticity [3]. Pathologically, the accumulation of gangliosides due to degradative enzyme deficiencies leads to lysosomal storage diseases such as Tay-Sachs, Sandhoff, and Gaucher diseases [4]. Consequently, the biosynthetic pathway is a major therapeutic target for substrate reduction therapy (SRT), where small molecule inhibitors like miglustat and eliglustat are used to decrease the production of these lipids to manageable levels [5]. Furthermore, certain gangliosides like GD2 and GD3 are highly expressed in neuroectoderm-derived tumors, making them targets for immunotherapy in cancers like neuroblastoma and melanoma [6]. Therapeutic strategies also explore modulating this pathway to treat neurodegenerative conditions like Parkinson's disease, where ganglioside imbalances are observed [3]. Overall, targeting ganglioside biosynthesis provides a versatile approach for managing both metabolic and oncological disorders.

Other names

Ganglioside biosynthesisGlycosphingolipid biosynthesisSialosphingolipid metabolismGanglioside metabolic pathway

Substrate reduction therapy (SRT) via inhibition of glucosylceramide synthase (GCS), the rate-limiting enzyme in the ganglioside biosynthetic pathway, to reduce the accumulation of downstream glycosphingolipids.